Method of collecting and analyzing a sample of blood when monitoring heparin therapy

• US 4,871,677 A
• Filed: 08/17/1988
• Issued: 10/03/1989
• Est. Priority Date: 02/25/1985
• Status: Expired due to Term

• Current Assignee: Hemotec Incorporated (Medtronic Plc)
• Original Assignee: Hemotec Incorporated (Medtronic Plc)
• Inventors: Baugh, Robert F., Taylor, Cynthia A.
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): NOT, DEFINED
• Application Number:
  US07/233,207
• Time in Patent Office: 412 Days
• Field of Search: 436/63, 436/69, 436/18, 436/176, 435/13, 435/2, 424/101
• US Class Current: 436/69
• CPC Class Codes: C12Q 1/56 involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• CPC Class Codes: Y10T 436/108331 Preservative, buffer, anticoagulant or diluent
• CPC Class Codes: Y10T 436/2525 Stabilizing or preserving

Abstract

An inhibitor of platelet-related procoagulant activity is included in a collection medium into which a whole blood sample is collected. The inhibitor prevents an initial drop in the recalcified activated clotting time measured during an assay test conducted on the whole blood sample collected in citrate in the medium. The discovery of the problem of the initial drop in the activated clotting time and the solution of including the inhibitor of the procoagulant activity is of considerable importance in heparin therapy, since the initial drop in the activated clotting time of heparinized blood is substantial. The inhibitor can be included with a calcium chelating agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet thromboxane A2 synthesis, are effective inhibitors of this platelet-related procoagulant activity.

Claims

1. A method of collecting and analyzing a sample of blood when monitoring heparin therapy, comprising the steps of:

drawing a sample of blood from the patient;

collecting the sample as it is drawn in a collection medium which includes a calcium chelating agent;

mixing an inhibitor with the blood sample approximately simultaneously with collection of the sample, the inhibitor being effective to inhibit a platelet-related procoagulant activity which otherwise normally occurs and substantially concludes within approximately thirty minutes after drawing the blood sample from the patient; and

thereafter

performing a recalcified activated clotting time test on the blood sample to obtain data useful in monitoring the amount of heparin to be administered.

2. A method as defined in claim 1, wherein the recalcified activated clotting time test is performed more than thirty minutes after the sample of blood was drawn.

3. A method as defined in claim 1 wherein the inhibitor is one of the group consisting of a prostaglandin or an inhibitor of thromboxane A2 synthesis.

4. A method as defined in claim 3 wherein the inhibitor is a prostaglandin and the prostaglandin is a prostacyclin.

5. A method as defined in claim 4 wherein:

the prostacyclin is present in the collection medium in an approximate concentration of 10 nanograms per milliliter of blood to be collected, and

the calcium chelating agent is sodium citrate present in the collection medium in an approximate concentration of 3.8% mg per 100 ml of water.

6. A method as defined in claim 3 wherein the inhibitor is an inhibitor of thromboxane A2 synthesis and said inhibitor is imidazole.

7. A method as defined in claim 6 wherein:

the imidazole is present in the collection medium in the approximate concentration of 50 mM, and

the calcium chelating agent is sodium citrate present in the collection medium in an approximate concentration of 3.8% mg per 100 ml of water.